Editorial: Is adequate relief fatally flawed or adequate as an end point in irritable bowel syndrome

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

There is controversy on the validity of binary end points used in irritable bowel syndrome (IBS) clinical trials. In a usual-care observational study, baseline severity influenced the response measured as satisfactory relief. This editorial reviews the observations from a non-pharmacological study to assess the effect of baseline severity on the performance of binary end points in large drug trials. The pivotal finding is that once the patients who reported adequate relief at baseline were excluded from the analysis, baseline severity no longer affected the proportion of patients reporting adequate relief of IBS with treatment. As large drug trials enriched the study cohorts for at least moderate severity after a no-treatment, run-in period, it seems likely that the precaution of excluding mild disease de facto resolved the hypothetical weakness of the adequate relief end point. Given the high responsiveness and longitudinal construct validity demonstrated with adequate relief end point, it should be accepted as a trial end point.

Original languageEnglish (US)
Pages (from-to)920-922
Number of pages3
JournalAmerican Journal of Gastroenterology
Volume104
Issue number4
DOIs
StatePublished - 2009

Fingerprint

Irritable Bowel Syndrome
Pharmaceutical Preparations
Observational Studies
Cohort Studies
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

@article{e91c9e5d800d44529047982597d71b3b,
title = "Editorial: Is adequate relief fatally flawed or adequate as an end point in irritable bowel syndrome",
abstract = "There is controversy on the validity of binary end points used in irritable bowel syndrome (IBS) clinical trials. In a usual-care observational study, baseline severity influenced the response measured as satisfactory relief. This editorial reviews the observations from a non-pharmacological study to assess the effect of baseline severity on the performance of binary end points in large drug trials. The pivotal finding is that once the patients who reported adequate relief at baseline were excluded from the analysis, baseline severity no longer affected the proportion of patients reporting adequate relief of IBS with treatment. As large drug trials enriched the study cohorts for at least moderate severity after a no-treatment, run-in period, it seems likely that the precaution of excluding mild disease de facto resolved the hypothetical weakness of the adequate relief end point. Given the high responsiveness and longitudinal construct validity demonstrated with adequate relief end point, it should be accepted as a trial end point.",
author = "Michael Camilleri",
year = "2009",
doi = "10.1038/ajg.2009.20",
language = "English (US)",
volume = "104",
pages = "920--922",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Editorial

T2 - Is adequate relief fatally flawed or adequate as an end point in irritable bowel syndrome

AU - Camilleri, Michael

PY - 2009

Y1 - 2009

N2 - There is controversy on the validity of binary end points used in irritable bowel syndrome (IBS) clinical trials. In a usual-care observational study, baseline severity influenced the response measured as satisfactory relief. This editorial reviews the observations from a non-pharmacological study to assess the effect of baseline severity on the performance of binary end points in large drug trials. The pivotal finding is that once the patients who reported adequate relief at baseline were excluded from the analysis, baseline severity no longer affected the proportion of patients reporting adequate relief of IBS with treatment. As large drug trials enriched the study cohorts for at least moderate severity after a no-treatment, run-in period, it seems likely that the precaution of excluding mild disease de facto resolved the hypothetical weakness of the adequate relief end point. Given the high responsiveness and longitudinal construct validity demonstrated with adequate relief end point, it should be accepted as a trial end point.

AB - There is controversy on the validity of binary end points used in irritable bowel syndrome (IBS) clinical trials. In a usual-care observational study, baseline severity influenced the response measured as satisfactory relief. This editorial reviews the observations from a non-pharmacological study to assess the effect of baseline severity on the performance of binary end points in large drug trials. The pivotal finding is that once the patients who reported adequate relief at baseline were excluded from the analysis, baseline severity no longer affected the proportion of patients reporting adequate relief of IBS with treatment. As large drug trials enriched the study cohorts for at least moderate severity after a no-treatment, run-in period, it seems likely that the precaution of excluding mild disease de facto resolved the hypothetical weakness of the adequate relief end point. Given the high responsiveness and longitudinal construct validity demonstrated with adequate relief end point, it should be accepted as a trial end point.

UR - http://www.scopus.com/inward/record.url?scp=65449123189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449123189&partnerID=8YFLogxK

U2 - 10.1038/ajg.2009.20

DO - 10.1038/ajg.2009.20

M3 - Article

C2 - 19293789

AN - SCOPUS:65449123189

VL - 104

SP - 920

EP - 922

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 4

ER -